Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Czech Academy of Sciences | OTHER |
Not provided
Not provided
Not provided
Not provided
Recent data suggest that the brain-gut axis, chronic intestinal inflammation and microbiome may contribute to the pathogenesis of neurodegenerative diseases with alfa-synucleinopathy, which include Parkinson's disease (PD) and Multiple system atrophy (MSA). Environmental factors e.g. diets, microbiome, metabolites and immune mechanisms may play important role in pathogenesis of these diseases. In the human arm of this project, the investigators will address effects of an anti-inflammatory gluten-free diet (GFD) on motor and non-motor symptoms as well as its effects on immune and metabolomic characteristics in patients with PD and MSA. In the mouse arm, the investigations will focus on the effects of GFD in chronic MPTP-induced mouse model of PD in various settings (e.g. in young or aged animals, with respect to the lengths of exposure to GFD). The chronic MPTP model will be used to assess the effects of GFD on adaptive and immune characteristics, and metabolic signatures. Using germ-free animals, the microbiome-dependency of the GFD-mediated effects may be determined. The anti-inflammatory gluten-free diet and its related mechanisms represent novel, promising and relatively straightforward approach in a search to improve symptoms of PD as well as MSA or even in their prevention.
This project is based on two research lines, testing the effect of gluten-free diet in a patients with PD and MSA (a human prospective trial) and in the chronic MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine)-induced mouse model of PD.
Research line 1. Assessments of effects of gluten-free diet (GFD) on clinical symptoms of Parkinson's disease (PD) and multiple system atrophy (MSA) in a prospective, controlled, randomized, rater-blinded human study. The goal of the research line 1 is to assess the effects of 12 months of administration of GFD on clinical symptoms of PD and MSA.
Research line 2. Effects of GFD on the development of PD in the chronic MPTP-induced mouse model of PD. The goal of the research line 2 is to study the effects of GFD in the chronic MPTP-induced mouse model of PD in order to evaluate its impact on clinical development of PD's features as well as immune and metabolomic characteristics that should shed more light on the possible mechanisms and potential novel treatment opportunities.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| PD gluten-free diet group | Experimental | Subjects with PD on gluten-free diet, ie. excluding all gluten-containing food during the day. |
|
| PD gluten-containing diet group | No Intervention | Subjects with PD on regular, gluten-containing diet, i.e. no restrictions during eating. | |
| MSA gluten-free diet group | Experimental | Subjects with PD on gluten-free diet, ie. excluding all gluten-containing food during the day. |
|
| MSA gluten-containing diet group | No Intervention | Subjects with MSA on regular gluten-containing diet, i.e. no restrictions during eating. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| gluten-free diet | Other | Diet excluding foods containing gluten. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change in severity of the clinical symptoms | Scored by the MDS-Unified Parkinson's Disease Rating Scale (scores ranging from 0 to 260, higher scores indicate greater impairment) or Unified Multiple System Atrophy Rating Scale (scores ranging from 0 to 104, higher scores indicate greater impairment). | Baseline, 1.5, 3, 6, 9, 12 and 13 months |
| Measure | Description | Time Frame |
|---|---|---|
| Cognition change | Scored by Montreal Cognitive Assessment (scores ranging from 0 to 30, lower scores indicate greater impairment). | Baseline, 1.5, 3, 6, 9, 12 and 13 months |
| Change in severity of the autonomic symptoms (Autonomic Scale for Outcomes in Parkinson's Disease) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Hana Brožová, MD, PhD | Contact | 224965539 | 00420 | hana.brozova@lf1.cuni.cz |
| Kamila Poláková, MD, PhD | Contact | 224965539 | 00420 | kamila.polakova@vfn.cz |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| GUHPrague | Recruiting | Prague | Czechia |
Not provided
| ID | Term |
|---|---|
| D010300 | Parkinson Disease |
| D019578 | Multiple System Atrophy |
| ID | Term |
|---|---|
| D020734 | Parkinsonian Disorders |
| D001480 | Basal Ganglia Diseases |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D055050 | Diet, Gluten-Free |
| ID | Term |
|---|---|
| D004035 | Diet Therapy |
| D044623 | Nutrition Therapy |
| D013812 | Therapeutics |
| D004032 | Diet |
| D009747 |
Not provided
Not provided
Study groups in PD and MSA group with gluten-free diet and on regular gluten-containing diet. Randomization: patients will be randomized by diagnosis, age and disease duration, a numbered envelope in 1:1 ration to gluten-free diet group and regular gluten-containing diet group will be used.
Not provided
Not provided
Not provided
Scored by Autonomic Scale for Outcomes in Parkinson's Disease (scores ranging from 0 to 69, higher scores indicate greater impairment). |
| Baseline, 1.5, 3, 6, 9, 12 and 13 months |
| Change in spatio temporal parameters of the gait | Investigated by GaitRite system | Baseline, 1.5, 3, 6, 9, 12 and 13 months |
| Quality of sleep change | Scored by Pittsburgh Sleep Quality Index | Baseline, 1.5, 3, 6, 9, 12 and 13 months |
| Mood change | Scored by Beck depression inventory (scores ranging from 0 to 63, higher scores indicate greater impairment). | Baseline, 1.5, 3, 6, 9, 12 and 13 months |
| Change in quality of life | Scored by Quality of life questionnaire (scores ranging from 0 to 100, higher scores indicate greater impairment). | Baseline, 1.5, 3, 6, 9, 12 and 13 months |
| D009422 | Nervous System Diseases |
| D009069 | Movement Disorders |
| D000080874 | Synucleinopathies |
| D019636 | Neurodegenerative Diseases |
| D054969 | Primary Dysautonomias |
| D001342 | Autonomic Nervous System Diseases |
| Nutritional Physiological Phenomena |
| D000066888 | Diet, Food, and Nutrition |
| D010829 | Physiological Phenomena |